Use of a combined gene expression profile in implementing a drug sensitivity predictive model for breast cancer

Xianglan Zhang, In Ho Cha, Ki Yeol Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed in order to reduce the side effects. Materials and Methods Various computational approaches have been proposed for predicting chemosensitivity based on gene expression profiles. A linear regression model can be used to predict the response of cancer cells to chemotherapeutic drugs, based on genomic features of the cells, and appropriate sample size for this method depends on the number of predictors. We used principal component analysis and identified a combined gene expression profile to reduce the number of predictors Results The coefficients of determinanation (R2) of prediction models with combined gene expression and several independent gene expressions were similar. Corresponding F values, which represent model significances were improved by use of a combined gene expression profile, indicating that the use of a combined gene expression profile is helpful in predicting drug sensitivity. Even better, a prediction model can be used even with small samples because of the reduced number of predictors. Conclusion Combined gene expression analysis is expected to contribute to more personalized management of breast cancer cases by enabling more effective targeting of existing therapies. This procedure for identifying a cell-type-specific gene expression profile can be extended to other chemotherapeutic treatments and many other heterogeneous cancer types.

Original languageEnglish
Pages (from-to)116-128
Number of pages13
JournalCancer Research and Treatment
Volume49
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Transcriptome
Breast Neoplasms
Pharmaceutical Preparations
Gene Expression
Linear Models
Neoplasms
Principal Component Analysis
Sample Size
Genotype
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{768c36b0af414b51b075d94507c1992b,
title = "Use of a combined gene expression profile in implementing a drug sensitivity predictive model for breast cancer",
abstract = "Purpose Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed in order to reduce the side effects. Materials and Methods Various computational approaches have been proposed for predicting chemosensitivity based on gene expression profiles. A linear regression model can be used to predict the response of cancer cells to chemotherapeutic drugs, based on genomic features of the cells, and appropriate sample size for this method depends on the number of predictors. We used principal component analysis and identified a combined gene expression profile to reduce the number of predictors Results The coefficients of determinanation (R2) of prediction models with combined gene expression and several independent gene expressions were similar. Corresponding F values, which represent model significances were improved by use of a combined gene expression profile, indicating that the use of a combined gene expression profile is helpful in predicting drug sensitivity. Even better, a prediction model can be used even with small samples because of the reduced number of predictors. Conclusion Combined gene expression analysis is expected to contribute to more personalized management of breast cancer cases by enabling more effective targeting of existing therapies. This procedure for identifying a cell-type-specific gene expression profile can be extended to other chemotherapeutic treatments and many other heterogeneous cancer types.",
author = "Xianglan Zhang and Cha, {In Ho} and Kim, {Ki Yeol}",
year = "2017",
month = "1",
day = "1",
doi = "10.4143/crt.2016.085",
language = "English",
volume = "49",
pages = "116--128",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "1",

}

Use of a combined gene expression profile in implementing a drug sensitivity predictive model for breast cancer. / Zhang, Xianglan; Cha, In Ho; Kim, Ki Yeol.

In: Cancer Research and Treatment, Vol. 49, No. 1, 01.01.2017, p. 116-128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of a combined gene expression profile in implementing a drug sensitivity predictive model for breast cancer

AU - Zhang, Xianglan

AU - Cha, In Ho

AU - Kim, Ki Yeol

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed in order to reduce the side effects. Materials and Methods Various computational approaches have been proposed for predicting chemosensitivity based on gene expression profiles. A linear regression model can be used to predict the response of cancer cells to chemotherapeutic drugs, based on genomic features of the cells, and appropriate sample size for this method depends on the number of predictors. We used principal component analysis and identified a combined gene expression profile to reduce the number of predictors Results The coefficients of determinanation (R2) of prediction models with combined gene expression and several independent gene expressions were similar. Corresponding F values, which represent model significances were improved by use of a combined gene expression profile, indicating that the use of a combined gene expression profile is helpful in predicting drug sensitivity. Even better, a prediction model can be used even with small samples because of the reduced number of predictors. Conclusion Combined gene expression analysis is expected to contribute to more personalized management of breast cancer cases by enabling more effective targeting of existing therapies. This procedure for identifying a cell-type-specific gene expression profile can be extended to other chemotherapeutic treatments and many other heterogeneous cancer types.

AB - Purpose Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed in order to reduce the side effects. Materials and Methods Various computational approaches have been proposed for predicting chemosensitivity based on gene expression profiles. A linear regression model can be used to predict the response of cancer cells to chemotherapeutic drugs, based on genomic features of the cells, and appropriate sample size for this method depends on the number of predictors. We used principal component analysis and identified a combined gene expression profile to reduce the number of predictors Results The coefficients of determinanation (R2) of prediction models with combined gene expression and several independent gene expressions were similar. Corresponding F values, which represent model significances were improved by use of a combined gene expression profile, indicating that the use of a combined gene expression profile is helpful in predicting drug sensitivity. Even better, a prediction model can be used even with small samples because of the reduced number of predictors. Conclusion Combined gene expression analysis is expected to contribute to more personalized management of breast cancer cases by enabling more effective targeting of existing therapies. This procedure for identifying a cell-type-specific gene expression profile can be extended to other chemotherapeutic treatments and many other heterogeneous cancer types.

UR - http://www.scopus.com/inward/record.url?scp=85010338133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010338133&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.085

DO - 10.4143/crt.2016.085

M3 - Article

C2 - 27188202

AN - SCOPUS:85010338133

VL - 49

SP - 116

EP - 128

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -